Observational studyJPEN. Journal of parenteral and enteral nutrition2020
An Observational Study of Smoflipid vs Intralipid on the Evolution of Intestinal Failure-Associated Liver Disease in Infants With Intestinal Failure.
Observational study in JPEN. Journal of parenteral and enteral nutrition, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 35 citations in OpenAlex.
- Conversion of Omega-6 to Omega-3 Fatty Acids Protects Against Liver Injury in a Murine Model.The Journal of surgical research · 2026Article
- Association between mixed fatty acid emulsion and parenteral nutrition-associated cholestasis in extremely low-birth-weight infants: A retrospective cohort study.JPEN. Journal of parenteral and enteral nutrition · 2025Article
- Association between multioil intravenous lipid emulsion and cholestasis in infants with gastrointestinal disorders: A retrospective cohort study.JPEN. Journal of parenteral and enteral nutrition · 2025Article
- Feeding Approach to Optimizing Nutrition in Infants with Congenital Heart Disease.Journal of cardiovascular development and disease · 2025Review
- Comparison of two formulations of intravenous lipid emulsions in pediatric intestinal failure.Pediatric surgery international · 2024Article
- Review
- Clinical challenges of short bowel syndrome and the path forward for organoid-based regenerative medicine.Regenerative therapy · 2023Review
- Comparative Study of Nanoparticle Blood Circulation after Forced Clearance of Own Erythrocytes (Mononuclear Phagocyte System-Cytoblockade) or Administration of Cytotoxic Doxorubicin- or Clodronate-Loaded Liposomes.International journal of molecular sciences · 2023Article
- Comparing mixed oil to soybean oil lipid emulsion in patients on home parenteral nutrition: a pilot prospective double-blind, crossover, randomized trial.Pilot and feasibility studies · 2023Article
- SO,MCT,OO,FO-ILE Is Associated With Better Side Effect Profile Than SO-ILE in Critically Ill Children Receiving Parenteral Nutrition.The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG · 2023Article
- Incidence and development of cholestasis in surgical neonates receiving an intravenous mixed-oil lipid emulsion.JPEN. Journal of parenteral and enteral nutrition · 2023Article
- Article
- An overview of the current management of short-bowel syndrome in pediatric patients.Surgery today · 2022Review
- Parenteral Fish-Oil Containing Lipid Emulsions Limit Initial Lipopolysaccharide-Induced Host Immune Responses in Preterm Pigs.Nutrients · 2021Article
- Multidisciplinary Management in Pediatric Ultrashort Bowel Syndrome.Journal of multidisciplinary healthcare · 2020Review
- Characteristics and clinical outcomes of pediatric patients following massive bowel resection: A retrospective cohort study.Intestinal Failure (New York, N.Y.)Article
- Conversion from SMOFlipid® to Omegaven® as a salvage therapy for intestinal failure associated liver disease.Intestinal Failure (New York, N.Y.)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 2 countries.
Funding
Abstract
backgroundSMOFlipid has a more diverse lipid profile than traditional Intralipid and has become the standard lipid for patients in our intestinal rehabilitation program. Our objective was to compare outcomes in neonates with intestinal failure (IF) who received SMOFlipid against those receiving Intralipid.
methodsThis was a retrospective cohort study of infants with IF with a minimum follow-up of 12 months in 2008-2016. Patients were stratified into 2 groups: group 1 received SMOFlipid; group 2 was a historical cohort who received Intralipid. The primary outcome was liver function evaluated using conjugated bilirubin (CB) levels. Statistical analysis included the Mann-Whitney U and χ
resultsThirty-seven patients were evaluated (17 = SMOFlipid, 20 = Intralipid). SMOFlipid patients were less likely to reach CB of 34 (24% vs 55%, P = 0.05), 50 µmol/L (11.8% vs 45%; P = 0.028), and did not require Omegaven (0% vs 30%; P = 0.014). CB level at 3 months after initiation of parenteral nutrition (PN) was lower in patients receiving SMOFlipid (0 vs 36 µmol/L; P = 0.01). Weight z-scores were improved for patients receiving SMOFlipid at 3 months (-0.932 vs -2.092; P = 0.028) and 6 months (-0.633 vs -1.614; P = 0.018). There were no differences in PN-supported patients or demographics between the groups.
conclusionUse of SMOFlipid resulted in decreased development of IF-associated liver disease in patients with IF when assessed using biochemical tests.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.